Imaging of Misfolded Proteins

Protein Misfolding Diseases: Current and Emerging Principles and Therapies

Volumn , Issue , 2010, Pages 645-671

  Levine, Harry ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

diagnosis and current therapies, imaging of misfolded proteins and disease biomarkers; Individual plaque detection microNMR imaging; Protein misfolding, recognized as a primary etiology in increasing number of diseases

Indexed keywords

EID: 84886213658     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470572702.ch30     Document Type: Chapter

References (130)

1. Agdeppa, E.D., Kepe, V., Liu, J., Small, G.W., Huang, S.C., Petric, A., Satyamurthy, N., Barrio, J.R. (2003). 2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease. Mol Imaging Biol, 5, 404-417.
2. Agdeppa, E.D., Kepe, V., Petri, A., Satyamurthy, N., Liu, J., Huang, S.C., Small, G.W., Cole, G.M., Barrio, J.R. (2003). In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl) amino]-2-naphthyl]ethylidene)malono nitrile. Neuroscience, 117, 723-730.
3. Anthony, J.C., Breitner, J.C., Zandi, P.P., Meyer, M.R., Jurasova, I., Norton, M.C., Stone, S.V. (2000). Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology, 54, 2066-2071.
4. Bacskai, B.J., Hickey, G.A., Skoch, J., Kajdasz, S.T., Wang, Y., Huang, G.F., Mathis, C.A., Klunk, W.E., Hyman, B.T. (2003). Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-{beta} ligand in transgenic mice. Proc Natl Acad Sci U S A, 100, 12462-12467.
5. Banks, W.A., Terrell, B., Farr, S.A., Robinson, S.M., Nonaka, N., Morley, J.E. (2002). Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides, 23, 2223-2226.
6. Benveniste, H., Einstein, G., Kim, K.R., Hulette, C., Johnson, G.A. (1999). Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. Proc Natl Acad Sci U S A, 96, 14079-14084.
7. Boxer, A.L., Rabinovici, G.D., Kepe, V., Goldman, J., Furst, A.J., Huang, S.C., Baker, S.L., O'Neil J.P., Chui, H., Geschwind, M.D., et al. (2007). Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease. Neurology, 69, 283-290.
8. Boyle, P.A., Wilson, R.S., Aggarwal, N.T., Tang, Y., Bennett, D.A. (2006). Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline. Neurology, 67, 441-445.
9. Braak, H., Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl), 82, 239-259.
10. Braak, H., Braak, E. (1995). Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging, 16, 271-278; discussion, 278-284.
11. Brandt, R., Hundelt, M., Shahani, N. (2005). Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. Biochim Biophys Acta, 1739, 331-354.
12. Bresjanac, M., Smid, L.M., Vovko, T.D., Petric, A., Barrio, J.R., Popovic, M. (2003). Molecular-imaging probe 2-(1-[6-[(2-fluoroethyl)(methyl) amino]-2-naphthyl] ethylidene) malononitrile labels prion plaques in vitro. J Neurosci, 23, 8029-8033.
13. Byeon, S.R., Jin, Y.J., Lim, S.J., Lee, J.H., Yoo, K.H., Shin, K.J., Oh, S.J., Kim, D.J. (2007). Ferulic acid and benzothiazole dimer derivatives with high binding affinity to beta-amyloid fibrils. Bioorg Med Chem Lett, 17, 4022-4025.
14. Caflisch, A. (2006). Computational models for the prediction of polypeptide aggregation propensity. Curr Opin Chem Biol, 10, 437-444.
15. Cai, L., Chin, F.T., Pike, V.W., Toyama, H., Liow, J.S., Zoghbi, S.S., Modell, K., Briard, E., Shetty, H.U., Sinclair, K., et al. (2004). Synthesis and evaluation of two (18)F-labeled 6-Iodo-2-(4u-N,N-dimethylamino)phenylimidazo[1,2-a]pyridine derivatives as prospective radioligands for beta-amyloid in Alzheimer's disease. J Med Chem, 47, 2208-2218.
16. Cai, L., Liow, J.S., Zoghbi, S.S., Cuevas, J., Baetas, C., Hong, J., Shetty, H.U., Seneca, N.M., Brown, A.K., Gladding, R., et al. (2008). Synthesis and evaluation of N-methyl and S-methyl (11)C-labeled 6-methylthio-2-(4u-N,N-dimethylamino)phenylimidazo[ 1,2-a]pyridines as radioligands for imaging beta-amyloid plaques in Alzheimer's disease. J Med Chem, 51, 148-158.
17. Chandra, R., Oya, S., Kung, M.P., Hou, C., Jin, L.W., Kung, H.F. (2007). New diphenylacetylenes as probes for positron emission tomographic imaging of amyloid plaques. J Med Chem, 50, 2415-2423.
18. Chang, Y.S., Jeong, J.M., Lee, Y.S., Kim, H.W., Ganesha, R.B., Kim, Y.J., Lee, D.S., Chung, J.K., Lee, M.C. (2006). Synthesis and evaluation of benzothiophene derivatives as ligands for imaging beta-amyloid plaques in Alzheimer's disease. Nucl Med Biol, 33, 811-820.
19. Chertkow, H., Black, S. (2007). Imaging biomarkers and their role in dementia clinical trials. Can J Neurol Sci, 34 Suppl 1, S77-S83.
20. Chiti, F., Dobson, C.M. (2006). Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem, 75, 333-366.
21. Cohen, R.M. (2007). The application of positron-emitting molecular imaging tracers in Alzheimer's disease. Mol Imaging Biol, 9, 204-216.
22. Coimbra, A., Williams, D.S., Hostetler, E.D. (2006). The role of MRI and PET/ SPECT in Alzheimer's disease. Curr Top Med Chem, 6, 629-647.
23. Cruz, L., Urbanc, B., Buldyrev, S.V., Christie, R., Gomez-Isla, T., Havlin, S., MaNamara, M., Stanley, H.E., Hyman, B.T. (1997). Aggregation and disaggregation of senile plaques in Alzheimer disease. Proc Natl Acad Sci U S A, 97, 7612-7616.
24. Crystal, A.S., Giasson, B.I., Crowe, A., Kung, M.P., Zhuang, Z.P., Trojanowski, J.Q., Lee, V.M. (2003). A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114. J Neurochem, 86, 1359-1368.
25. de Jong, D., Kremer, B.P., Olde Rikkert, M.G., Verbeek, M.M. (2007). Current state and future directions of neurochemical biomarkers for Alzheimer's disease. Clin Chem Lab Med, 45, 1421-1434.
26. Deane, R., Zlokovic, B.V. (2007). Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res, 4, 191-197.
27. Dhenain, M., Privat, N., Duyckaerts, C., Jacobs, R.E. (2002). Senile plaques do not induce susceptibility effects in T2*-weighted MR microscopic images. NMR Biomed, 15, 197-203.
28. El Tayara Nel, T., Volk, A., Dhenain, M., Delatour, B. (2007). Transverse relaxation time reflects brain amyloidosis in young APP/PS1 transgenic mice. Magn Reson Med, 58, 179-184.
29. Elhaddaoui, A., Pigorsch, E., Delacourte, A., Turrell, S. (1995). Competition of Congo Red and thioflavin S binding to amyloid sites in Alzheimer's diseased brain. Biospectroscopy, 1, 351-356.
30. Faber, C., Zahneisen, B., Tippmann, F., Schroeder, A., Fahrenholz, F. (2007). Gradient-echo and CRAZED imaging for minute detection of Alzheimer plaques in an APP(V717I) × ADAM10-dn mouse model. Magn Reson Med, 57, 696-703.
31. Fandrich, M. (2007). On the structural definition of amyloid fibrils and other polypeptide aggregates. Cell Mol Life Sci, 64, 2066-2078.
32. Ferreira, S.T., Vieira, M.N., De Felice, F.G. (2007). Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life, 59, 332-345.
33. Fink, A.L. (2005). Natively unfolded proteins. Curr Opin Struct Biol, 15, 35-41.
34. Flaherty, D.P., Walsh, S.M., Kiyota, T., Dong, Y., Ikezu, T., Vennerstrom, J.L. (2007). Polyfluorinated bis-styrylbenzene beta-amyloid plaque binding ligands. J Med Chem, 50, 4986-4992.
35. Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G., Wall, A., Ringheim, A., Langstrom, B., Nordberg, A. (2008). PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging, 29, 1456-1465.
36. Galzitskaya, O.V., Garbuzynskiy, S.O., Lobanov, M.Y. (2006). Prediction of amyloidogenic and disordered regions in protein chains. PLoS Comput Biol, 2, e177.
37. Glenner, G.G. (1980). Amyloid deposits and amyloidosis. the beta-fibrilloses (first of two parts). N Engl J Med, 302, 1283-1292.
38. Glenner, G.G. (1980). Amyloid deposits and amyloidosis: the beta-fibrilloses (second of two parts). N Engl J Med, 302, 1333-1343.
39. Habicht, G., Haupt, C., Friedrich, R.P., Hortschansky, P., Sachse, C., Meinhardt, J., Wieligmann, K., Gellermann, G.P., Brodhun, M., Gotz, J., et al. (2007). Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing A protofibrils. Proc Natl Acad Sci U S A, 104, 19232-19237.
40. Haes, A.J., Chang, L., Klein, W.L., Van Duyne, R.P. (2005). Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. J Am Chem Soc, 127, 2264-2271.
41. Herland, A., Nilsson, K.P., Olsson, J.D., Hammarstrom, P., Konradsson, P., Inganas, O. (2005). Synthesis of a regioregular zwitterionic conjugated oligoelectrolyte, usable as an optical probe for detection of amyloid fibril formation at acidic pH. J Am Chem Soc, 127, 2317-2323.
42. Honson, N.S., Johnson, R.L., Huang, W., Inglese, J., Austin, C.P., Kuret, J. (2007). Differentiating Alzheimer disease-associated aggregates with small molecules. Neurobiol Dis, 28, 251-260.
43. Ishikawa, K., Kudo, Y., Nishida, N., Suemoto, T., Sawada, T., Iwaki, T., Doh-Ura, K. (2006). Styrylbenzoazole derivatives for imaging of prion plaques and treatment of transmissible spongiform encephalopathies. J Neurochem, 99, 198-205.
44. Jack, C.R., Jr., Marjanska, M., Wengenack, T.M., Reyes, D.A., Curran, G.L., Lin, J., Preboske, G.M., Poduslo, J.F., Garwood, M. (2007). Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: a new tool in Alzheimer's disease research. Neuroscientist, 13, 38-48.
45. Kandimalla, K.K., Curran, G.L., Holasek, S.S., Gilles, E.J., Wengenack, T.M., Ramirez-Alvarado, M., Poduslo, J.F. (2006). Physiological and biophysical factors that influence Alzheimer's disease amyloid plaque targeting of native and putrescine modified human amyloid {beta} 40. J Pharmacol Exp Ther, 318, 17-25.
46. Kandimalla, K.K., Wengenack, T.M., Curran, G.L., Gilles, E.J., Poduslo, J.F. (2007). Pharmacokinetics and amyloid plaque targeting ability of a novel peptidebased magnetic resonance contrast agent in wild type and Alzheimer's disease transgenic mice. J Pharmacol Exp Ther, 318, 17-25.
47. Kayed, R., Glabe, C.G. (2006). Conformation-dependent anti-amyloid oligomer antibodies. Methods Enzymol, 413, 326-344.
48. Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, C.W., Glabe, C.G. (2003). Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science, 300, 486-489.
49. Kemppainen, N.M., Aalto, S., Wilson, I.A., Nagren, K., Helin, S., Bruck, A., Oikonen, V., Kailajarvi, M., Scheinin, M., Viitanen, M., et al. (2007). PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology, 68, 1603-1606.
50. Kepe, V., Huang, S.C., Small, G.W., Satyamurthy, N., Barrio, J.R. (2006). Visualizing pathology deposits in the living brain of patients with Alzheimer's disease. Methods Enzymol, 412, 144-160.
51. Klunk, W.E., Debnath, M.L., Pettegrew, J.W. (1994). Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease. Neurobiol Aging, 15, 691-698.
52. Klunk, W.E., Debnath, M.L., Pettegrew, J.W. (1995). Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe. Neurobiol Aging, 16, 541-548.
53. Klunk, W.E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., Bergstrom, M., Savitcheva, I., Huang, G.F., Estrada, S., et al. (2004). Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol, 55, 306-319.
54. Klunk, W.E., Lopresti, B.J., Ikonomovic, M.D., Lefterov, I.M., Koldamova, R.P., Abrahamson, E.E., Debnath, M.L., Holt, D.P., Huang, G.F., Shao, L., et al. (2005). Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci, 25, 10598-10606.
55. Klunk, W.E., Wang, Y., Huang, G.F., Debnath, M.L., Holt, D.P., Mathis, C.A. (2001). Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci, 69, 1471-1484.
56. Klunk, W.E., Wang, Y., Huang, G.F., Debnath, M.L., Holt, D.P., Shao, L., Hamilton, R.L., Ikonomovic, M.D., DeKosky, S.T., Mathis, C.A. (2003). The binding of 2-(4u-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci, 23, 2086-2092.
57. Kodali, R., Wetzel, R. (2007). Polymorphism in the intermediates and products of amyloid assembly. Curr Opin Struct Biol, 17, 48-57.
58. Kung, H.F., Kung, M.P., Zhuang, Z.P., Hou, C., Lee, C.W., Plossl, K., Zhuang, B., Skovronsky, D.M., Lee, V.M., Trojanowski, J.Q. (2003). Iodinated tracers for imaging amyloid plaques in the brain. Mol Imaging Biol, 5, 418-426.
59. Kung, M.P., Hou, C., Zhuang, Z.P., Cross, A.J., Maier, D.L., Kung, H.F. (2004). Characterization of IMPY as a potential imaging agent for beta-amyloid plaques in double transgenic PSAPP mice. Eur J Nucl Med Mol Imaging, 31, 1136-1145.
60. Kung, M.P., Hou, C., Zhuang, Z.P., Skovronsky, D., Kung, H.F. (2004). Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease. Brain Res, 1025, 98-105.
61. Kung, M.P., Hou, C., Zhuang, Z.P., Zhang, B., Skovronsky, D., Trojanowski, J.Q., Lee, V.M., Kung, H.F. (2002). IMPY: an improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques. Brain Res, 956, 202-210.
62. Kung, M.P., Zhuang, Z.P., Hou, C., Kung, H.F. (2004). Development and evaluation of iodinated tracers targeting amyloid plaques for SPECT imaging. J Mol Neurosci, 24, 49-54.
63. Lambert, M.P., Velasco, P.T., Chang, L., Viola, K.L., Fernandez, S., Lacor, P.N., Khuon, D., Gong, Y., Bigio, E.H., Shaw, P., et al. (2007). Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem, 100, 23-35.
64. Levey, A., Lah, J., Goldstein, F., Steenland, K., Bliwise, D. (2006). Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease. Clin Ther, 28, 991-1001.
65. LeVine, H., III. (1993). Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci, 2, 404-410.
66. LeVine, H., III. (1995). Thioflavine T interaction with amyloid b-sheet structures. Amyloid: Int J Exp Clin Invest, 2, 1-6.
67. LeVine, H., III. (1999). Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol, 309, 274-284.
68. LeVine, H., III. (2005). Multiple ligand binding sites on A beta(1-40) fibrils. Amyloid, 12, 5-14.
69. Linding, R., Schymkowitz, J., Rousseau, F., Diella, F., Serrano, L. (2004). A comparative study of the relationship between protein structure and beta-aggregation in globular and intrinsically disordered proteins. J Mol Biol, 342, 345-353.
70. Lockhart, A., Ye, L., Judd, D.B., Merritt, A.T., Lowe, P.N., Morgenstern, J.L., Hong, G., Gee, A.D., Brown, J. (2005). Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils. J Biol Chem, 280, 7677-7684.
71. Lombardo, J.A., Stern, E.A., McLellan, M.E., Kajdasz, S.T., Hickey, G.A., Bacskai, B.J., Hyman, B.T. (2003). Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci, 23, 10879-10883.
72. Maeda, J., Ji, B., Irie, T., Tomiyama, T., Maruyama, M., Okauchi, T., Staufenbiel, M., Iwata, N., Ono, M., Saido, T.C., et al. (2007). Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci, 27, 10957-10968.
73. Marshall, J.R., Stimson, E.R., Ghilardi, J.R., Vinters, H.V., Mantyh, P.W., Maggio, J.E. (2002). Noninvasive imaging of peripherally injected Alzheimer's disease type synthetic A beta amyloid in vivo. Bioconjug Chem, 13, 276-284.
74. McLellan, M.E., Kajdasz, S.T., Hyman, B.T., Bacskai, B.J. (2003). In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy. J Neurosci, 23, 2212-2217.
75. Meyer-Luehmann, M., Coomaraswamy, J., Bolmont, T., Kaeser, S., Schaefer, C., Kilger, E., Neuenschwander, A., Abramowski, D., Frey, P., Jaton, A.L., et al. (2006). Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science, 313, 1781-1784.
76. Montalto, M.C., Farrar, G., Hehir, C.T. (2007). Fibrillar and oligomeric betaamyloid as distinct local biomarkers for Alzheimer's disease. Ann N Y Acad Sci, 1097, 239-258.
77. Naiki, H., Higuchi, K., Hosokawa, M., Takeda, T. (1989). Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T1. Anal Biochem, 177, 244-249.
78. Newberg, A.B., Wintering, N.A., Plossl, K., Hochold, J., Stabin, M.G., Watson, M., Skovronsky, D., Clark, C.M., Kung, M.P., Kung, H.F. (2006). Safety, biodistribution, and dosimetry of 123I-IMPY: a novel amyloid plaque-imaging agent for the diagnosis of alzheimer's disease. J Nucl Med, 47, 748-754.
79. Nilsson, K.P., Aslund, A., Berg, I., Nystrom, S., Konradsson, P., Herland, A., Inganas, O., Stabo-Eeg, F., Lindgren, M., Westermark, G.T., et al. (2007). Imaging distinct conformational states of amyloid-beta fibrils in Alzheimer's disease using novel luminescent probes. ACS Chem Biol, 2, 553-560.
80. Nilsson, K.P., Hammarstrom, P., Ahlgren, F., Herland, A., Schnell, E.A., Lindgren, M., Westermark, G.T., Inganas, O. (2006). Conjugated polyelectrolytes: conformation-sensitive optical probes for staining and characterization of amyloid deposits. Chembiochem, 7, 1096-1104.
81. Nilsson, K.P., Herland, A., Hammarstrom, P., Inganas, O. (2005). Conjugated polyelectrolytes: conformation-sensitive optical probes for detection of amyloid fibril formation. Biochemistry, 44, 3718-3724.
82. O'Nuallain, B., Shivaprasad, S., Kheterpal, I., Wetzel, R. (2005). Thermodynamics of abeta(1-40) amyloid fibril elongation. Biochemistry, 44, 12709-12718.
83. O'Nuallain, B., Williams, A.D., Westermark, P., Wetzel, R. (2004). Seeding specificity in amyloid growth induced by heterologous fibrils. J Biol Chem, 279, 17490-17499.
84. Oddo, S., Caccamo, A., Kitazawa, M., Tseng, B.P., LaFerla, F.M. (2003). Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging, 24, 1063-1070.
85. Okamura, N., Suemoto, T., Furumoto, S., Suzuki, M., Shimadzu, H., Akatsu, H., Yamamoto, T., Fujiwara, H., Nemoto, M., Maruyama, M., et al. (2005). Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. J Neurosci, 25, 10857-10862.
86. Ono, M., Kawashima, H., Nonaka, A., Kawai, T., Haratake, M., Mori, H., Kung, M.P., Kung, H.F., Saji, H., Nakayama, M. (2006). Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains. J Med Chem, 49, 2725-2730.
87. Ono, M., Maya, Y., Haratake, M., Ito, K., Mori, H., Nakayama, M. (2007). Aurones serve as probes of beta-amyloid plaques in Alzheimer's disease. Biochem Biophys Res Commun, 361, 116-121.
88. Ono, M., Yoshida, N., Ishibashi, K., Haratake, M., Arano, Y., Mori, H., Nakayama, M. (2005). Radioiodinated flavones for in vivo imaging of beta-amyloid plaques in the brain. J Med Chem, 48, 7253-7260.
89. Osmand, A.P., Berthelier, V., Wetzel, R. (2006). Imaging polyglutamine deposits in brain tissue. Methods Enzymol, 412, 106-122.
90. Petersen, R.C. (2004). Mild cognitive impairment as a diagnostic entity. J Intern Med, 256, 183-194.
91. Petkova, A.T., Leapman, R.D., Guo, Z., Yau, W.M., Mattson, M.P., Tycko, R. (2005). Self-propagating, molecular-level polymorphism in Alzheimer's betaamyloid fibrils. Science, 307, 262-265.
92. Petric, A., Jacobson, A.F., Barrio, J.R. (1998). Functionalization of a viscosity-sensitive fluorophore for probing of biological systems. Bioorg Med Chem Lett, 8, 1455-1460.
93. Poduslo, J.F., Ramakrishnan, M., Holasek, S.S., Ramirez-Alvarado,M., Kandimalla, K.K., Gilles, E.J., Curran, G.L., Wengenack, T.M. (2007). In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques. J Neurochem, 102, 420-433.
94. Price, J.C., Klunk, W.E., Lopresti, B.J., Lu, X., Hoge, J.A., Ziolko, S.K., Holt, D.P., Meltzer, C.C., Dekosky, S.T. Mathis, C.A. (2005). Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J Cereb Blood Flow Metab, 25, 1528-1547.
95. Qu, W., Kung, M.P., Hou, C., Benedum, T.E., Kung, H.F. (2007). Novel styrylpyridines as probes for SPECT imaging of amyloid plaques. J Med Chem, 50, 2157-2165.
96. Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L.F., Galasko, D.R., Jutel, M., Karydas, A., et al. (2007). Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med, 13, 1359-1362.
97. Rockwood, K. (2006). Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease. Acta Neurol Scand Suppl, 185, 71-77.
98. Sato, K., Higuchi, M., Iwata, N., Saido, T.C., Sasamoto, K. (2004). Fluorosubstituted and (13)C-labeled styrylbenzene derivatives for detecting brain amyloid plaques. Eur J Med Chem, 39, 573-578.
99. Schmidt, M.L., Schuck, T., Sheridan, S., Kung, M.P., Kung, H., Zhuang, Z.P., Bergeron, C., Lamarche, J.S., Skovronsky, D., Giasson, B.I., et al. (2001). The fluorescent Congo Red derivative, (trans, trans) -1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB), labels diverse beta-pleated sheet structures in postmortem human neurodegenerative disease brains. Am J Pathol, 159, 937-943.
100. Seneca, N., Cai, L., Liow, J.S., Zoghbi, S.S., Gladding, R.L., Hong, J., Pike, V.W., Innis, R.B. (2007). Brain and whole-body imaging in nonhuman primates with [(11)C]MeS-IMPY, a candidate radioligand for beta-amyloid plaques. Nucl Med Biol, 34, 681-689.
101. Serpell, L.C., Fraser, P.E., Sunde, M. (1999). X-ray fiber diffraction of amyloid fibrils. Methods Enzymol, 309, 526-536.
102. Serpell, L.C., Sunde, M., Benson, M.D., Tennent, G.A., Pepys, M.B., Fraser, P.E. (2000). The protofilament substructure of amyloid fibrils.JMolBiol, 300, 1033-1039.
103. Shoghi-Jadid, K., Barrio, J.R., Kepe, V., Huang, S.C. (2006). Exploring a mathematical model for the kinetics of beta-amyloid molecular imaging probes through a critical analysis of plaque pathology. Mol Imaging Biol, 8, 151-162.
104. Shoghi-Jadid, K., Barrio, J.R., Kepe, V., Wu, H.M., Small, G.W., Phelps, M.E., Huang, S.C. (2005). Imaging beta-amyloid fibrils in Alzheimer's disease: a critical analysis through simulation of amyloid fibril polymerization. Nucl Med Biol, 32, 337-351.
105. Simmons, M.K., Manjeshwar, R., Agdeppa, E.D., Mattheyses, R.M., Kiehl, T.R., Montalto, M.C. (2005). A computational positron emission tomography simulation model for imaging beta-amyloid in mice. Mol Imaging Biol, 7, 69-77.
106. Sipe, J.D., Cohen, A.S. (2000). Review: history of the amyloid fibril. J Struct Biol, 130, 88-98.
107. Small, G.W., Kepe, V., Ercoli, L.M., Siddarth, P., Bookheimer, S.Y., Miller, K.J., Lavretsky, H., Burggren, A.C., Cole, G.M., Vinters, H.V., et al. (2006). PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med, 355, 2652-2663.
108. Sonnen, J.A., Keene, C.D., Montine, K.S., Li, G., Peskind, E.R., Zhang, J., Montine, T.J. (2007). Biomarkers for Alzheimer's disease. Expert Rev Neurother, 7, 1021-1028.
109. Sparks, D.L., Sabbagh, M., Connor, D., Soares, H., Lopez, J., Stankovic, G., Johnson-Traver, S., Ziolkowski, C., Browne, P. (2006). Statin therapy in Alzheimer's disease. Acta Neurol Scand Suppl, 185, 78-86.
110. Styren, S.D., Hamilton, R.L., Styren, G.C., Klunk, W.E. (2000). X-34, a fluorescent derivative of Congo Red: a novel histochemical stain for Alzheimer's disease pathology. J Histochem Cytochem, 48, 1223-1232.
111. Suemoto, T., Okamura, N., Shiomitsu, T., Suzuki, M., Shimadzu, H., Akatsu, H., Yamamoto, T., Kudo, Y., Sawada, T. (2004). In vivo labeling of amyloid with BF-
112. Szekely, C.A., Thorne, J.E., Zandi, P.P., Ek, M., Messias, E., Breitner, J.C., Goodman, S.N. (2004). Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology, 23, 159-169.
113. Thal, L.J., Kantarci, K., Reiman, E.M., Klunk, W.E., Weiner, M.W., Zetterberg, H., Galasko, D., Pratico, D., Griffin, S., Schenk, D., Siemers, E. (2006). The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord, 20, 6-15.
114. Tseng, B.P., Esler, W.P., Clish, C.B., Stimson, E.R., Ghilardi, J.R., Vinters, H.V., Mantyh, P.W., Lee, J.P., Maggio, J.E. (1999). Deposition of monomeric, not oligomeric, Abeta mediates growth of Alzheimer's disease amyloid plaques in human brain preparations. Biochemistry, 38, 10424-10431.
115. Urbanc, B., Cruz, L., Buldyrev, S.V., Havlin, S., Irizarry, M.C., Stanley, H.E., Hyman, B.T. (1999). Dynamics of plaque formation in Alzheimer's disease. Biophys J, 76, 1330-1334.
116. Uversky, V.N. (2002). Natively unfolded proteins: a point where biology waits for physics. Protein Sci, 11, 739-756.
117. Virchow, R. (1854). Uber eine im Gehirn und Ruchenmark des Menschen aufgefundene Substanz mit der chemischen Reaktion der cellulose. Virchows Arch Pathol Anat, 6, 135-138.
118. Walker, L., LeVine, H., Jucker, M. (2006). Koch's postulates and infectious proteins. Acta Neuropathol, 112, 1-4.
119. Walker, L.C., Bian, F., Callahan, M.J., Lipinski, W.J., Durham, R.A., LeVine, H. (2002). Modeling Alzheimer's disease and other proteopathies in vivo: Is seeding the key? Review article. Amino Acids, 23, 87-93.
120. Walker, L.C., LeVine, H. (2000). The cerebral proteopathies. Neurobiol Aging, 21, 559-561.
121. Walker, L.C., LeVine, H. (2000). The cerebral proteopathies: neurodegenerative disorders of protein conformation and assembly. Mol Neurobiol, 21, 83-95.
122. Walker, L.C., LeVine, H., 3rd. (2002). Proteopathy: the next therapeutic frontier? Curr Opin Investig Drugs, 3, 782-787.
123. Walker, L.C., Levine, H., 3rd, Mattson, M.P., Jucker, M. (2006). Inducible proteopathies. Trends Neurosci, 29, 438-443.
124. Wang, Y., Klunk, W.E., Debnath, M.L., Huang, G.F., Holt, D.P., Shao, L., Mathis, C.A. (2004). Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease. J Mol Neurosci, 24, 55-62.
125. Wei, J., Wu, C., Lankin, D., Gulrati, A., Valyi-Nagy, T., Cochran, E., Pike, V.W., Kozikowski, A., Wang, Y. (2005). Development of novel amyloid imaging agents based upon thioflavin S. Curr Alzheimer Res, 2, 109-114.
126. Westermark, P. (2005). Aspects on human amyloid forms and their fibril polypeptides. FEBS J, 272, 5942-5949.
127. Westermark, P., Benson, M.D., Buxbaum, J.N., Cohen, A.S., Frangione, B., Ikeda, S., Masters, C.L., Merlini, G., Saraiva, M.J., Sipe, J.D. (2007). A primer of amyloid nomenclature. Amyloid, 14, 179-183.
128. Ye, L., Morgenstern, J.L., Gee, A.D., Hong, G., Brown, J., Lockhart, A. (2005). Delineation of PET imaging agent binding sites on beta-amyloid peptide fibrils. J Biol Chem, 280, 23599-23604.
129. Zandi, P.P., Sparks, D.L., Khachaturian, A.S., Tschanz, J., Norton, M., Steinberg, M., Welsh-Bohmer, K.A., Breitner, J.C. (2005). Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry, 62, 217-224.
130. Ziolko, S.K., Weissfeld, L.A., Klunk, W.E., Mathis, C.A., Hoge, J.A., Lopresti, B.J., Dekosky, S.T., Price, J.C. (2006). Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. Neuroimage, 33, 94-102.